Zydus Pharmaceuticals (USA) Inc., located in Pennington, New Jersey, has come a long way since our first commercial launch in August 2005. The company currently offers more than 500 SKUs to the US market and is ranked the fifth largest unbranded generic corporation in the US based on dispensed prescriptions (IQVIA, NPA Audit, MAT Oct 2022). Exceptional service to both customers and patients who rely on its products has been a key driver for our success. Zydus Pharmaceuticals remains diligent in ensuring a quality and affordable supply of our products in the US to provide continuity for the patients who use our medications.
While Zydus Pharmaceuticals has grown tremendously since it entered the US, we continue to look for new ways to bring value to the US market. We are focused on expanding our portfolio of complex generics, including modified release solid orals, transdermals, injectables, and oral suspensions to further our footprint in the lives of patients. To date, Zydus Pharmaceuticals has filed over 129 drug master files (DMFs), received final USFDA approval on 296 Abbreviated New Drug Applications (ANDAs), and has over 105 ANDAs pending approval with the USFDA. The company also has approximately 300 additional products in various stages of development.
As a company, our vision, mission, and purpose exemplify our commitment to science and our dedication to care and nurturance.
Be a global life-sciences company transforming lives through pathbreaking discoveries.
To unlock new possibilities in life-sciences through quality healthcare solutions that impact lives.
Empower people with the freedom to live healthier and more fulfilled lives.
To learn more, Contact Us.
Our Core Values
Driven by the purpose of delivering care for the patients that rely on our medications and backed by the power of innovation and science, Zydus strives to make a meaningful difference in serving patients and communities. The pillars of care, compassion, and commitment to innovation are at the heart of our core.
Zydus Lifesciences Limited
Zydus Lifesciences Limited, the parent company of Zydus Pharmaceuticals, is a fully integrated, global healthcare provider located in Ahmedabad, India. With a legacy of over 70 years, the company is driven by a passion for innovation and making a difference in the world of health and care. Zydus Lifesciences is India’s fourth largest pharmaceutical company with more than 30 manufacturing plants worldwide and business operations in 55 countries including, India, the US, France, Spain, Brazil, Mexico, and South Africa. As one of the key players amongst pharmaceutical manufacturing companies, Zydus Lifesciences has manufacturing capabilities across the entire pharmaceutical value chain including formulations, APIs, vaccines, biosimilars, complex products, animal health products, and wellness products. From new chemical entities to vaccines, biosimilars, novel biologics, and niche technologies, Zydus is exploring different ideas to develop differentiated medicines for the future. Zydus Lifescience’s ZyCoV-D vaccine was the world’s first plasmid DNA vaccine to be approved for human use and is currently approved in India as a two-dose regimen for adults and children aged 12 years and above. Zydus Lifesciences continues to innovate with an unswerving focus to address unmet healthcare needs and is dedicated to its mission of creating healthier, happier communities across the globe.
For more information, please visit www.zyduslife.com.
$2 billion +
Producing over 28 billion pills annually